Heatwurx (PCSA)
(Delayed Data from NSDQ)
$1.40 USD
+0.08 (6.06%)
Updated Oct 18, 2024 03:59 PM ET
After-Market: $1.40 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Price, Consensus and EPS Surprise
PCSA 1.40 +0.08(6.06%)
Will PCSA be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for PCSA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for PCSA
12 Health Care Stocks Moving In Thursday's After-Market Session
Buy Rating Affirmed for Processa Pharmaceuticals Amidst Promising Phase 2 Trial for NGC-Cap
Constellation Brands, Levi Strauss And 3 Stocks To Watch Heading Into Thursday
Closing Bell Movers: Levi Strauss down 10% on reduced FY24 revenue view
Processa Pharmaceuticals jumps 28% after Phase 2 study update